Vol. 19 No. 4-2 (2015): Cell Technologies in Cardiology (Special Issue)
REVIEWS

CRISPR/CAS9 system – a tool for studying hereditary cardiovascular diseases

PDF (Русский)
  • S. Medvedev,
  • S. Zakiyan
S. Medvedev
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Novosibirsk National Research State University, 2 Pirogova St., 630090 Novosibirsk, Russian Federation
S. Zakiyan
The Federal Research Center Institute of Cytology and Genetics, The Siberian Branch of the Russian Federation Academy of Sciences, 10 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Institute of Chemical Biology and Fundamental Medicine, The Siberian Branch of the Russian Federation Academy of Sciences, 8 Lavrentieva Avenue, 630090 Novosibirsk, Russian Federation; Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Ministry of Health Care of Russian Federation, 15 Rechkunovskaya St., 630055 Novosibirsk, Russian Federation; Novosibirsk National Research State University, 2 Pirogova St., 630090 Novosibirsk, Russian Federation
DOI: https://doi.org/10.21688/1681-3472-2015-4-2-113-117

Published 2016-01-14

Keywords

  • CRISPR/Cas9 system,
  • genomic engineering,
  • hereditary diseases of the cardiovascular system

How to Cite

Medvedev, S., & Zakiyan, S. (2016). CRISPR/CAS9 system – a tool for studying hereditary cardiovascular diseases. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 19(4-2), 113–117. https://doi.org/10.21688/1681-3472-2015-4-2-113-117

Copyright (c) 2016 Medvedev S.P., Zakiyan S.M.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

The search for more effective and safe drugs for cardiovascular diseases is one of the most urgent tasks of experimental cardiology and pharmacology. In the case of hereditary diseases of the cardiovascular system, particularly difficult is the search for the genes responsible for disease development and decoding of their interactions in the process of developing the disease. In addition, the current challenge is to identify genome single nucleotide polymorphisms that affect the degree of manifestation of disease. In recent years, rapidly developing areas related to the use of genome editing systems such as CRISPR/Cas9. CRISPR/Cas9 system is a convenient and relatively easy-to-use tool that can effectively contribute towards changes in the genomes of cultured human cells, to carry out the knockout genes control their transcription, make or correct gene mutations. In this review, an analysis of the latest advances in the use of CRISPR/Cas9 for research and treatment of diseases, and describes the prospects for its use for the study of cardiovascular disease and the search for new methods for their treatment.

PDF (Русский)

References

  1. Bezzina C.R., Lahrouchi N., Priori S.G. Genetics of sudden cardiac death // Circ. Res. 2015. Vol. 116. № 12. P. 1919–36.
  2. Hedley P.L., Jorgensen P., Schlamowitz S., Wangari R., Moolman-Smook J., Brink P.A., Kanters J.K., Corfield V.A., Christiansen M. The genetic basis of long QT and short QT syndromes: a mutation update // Hum. Mutat. 2009. Vol. 30. № 11. P. 1486–511.
  3. Mizusawa Y., Horie M., Wilde A.A. Genetic and clinical advances in congenital long QT syndrome // Circ. J. 2014. Vol. 78. № 12. P. 2827–33.
  4. Frey N., Luedde M., Katus H.A. Mechanisms of disease: hypertrophic cardiomyopathy // Nat. Rev. Cardiol. 2012. Vol. 9. № 2. P. 91–100.
  5. Borst O., Ochmann C., Schonberger T., Jacoby C., Stellos K., Seizer P., Flögel U., Lang F., Gawaz M. Methods employed for induction and analysis of experimental myocardial infarction in mice // Cell. Physiol. Biochem. 2011. Vol. 28. № 1. P. 1–12.
  6. Diaz J.A., Obi A.T., Myers D.D.Jr., Wrobleski S.K., Henke P.K., Mackman N., Wakefield T.W. Critical review of mouse models of venous thrombosis // Arterioscler. Thromb. Vasc. Biol. 2012. Vol. 32. № 3. P. 556–62.
  7. Jawien J. The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis // Curr. Pharm. Biotechnol. 2012. Vol. 13. № 13. P. 2435–9.
  8. Salama G., London B. Mouse models of long QT syndrome // J. Physiol. 2007. Vol. 578. Pt. 1. P. 43–53.
  9. Zaragoza C., Gomez-Guerrero C., Martin-Ventura J.L., Blanco-Colio L., Lavin B., Mallavia B., Tarin C., Mas S., Ortiz A., Egido J. Animal models of cardiovascular diseases // J. Biomed. Biotechnol. 2011. Vol. 2011. P. 497841.
  10. Medvedev S.P., Shevchenko A.I., Zakian S.M. Induced Pluripotent Stem Cells: Problems and Advantages when Applying them in Regenerative Medicine // Acta Naturae. 2010. Vol. 2. № 2. P. 18–28.
  11. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., Thomson J.A., Kamp T.J. Functional cardiomyocytes derived from human induced pluripotent stem cells // Circ. Res. 2009. Vol. 104. № 4. P. e30–41.
  12. Zwi L., Caspi O., Arbel G., Huber I., Gepstein A., Park I.H., Gepstein L. Cardiomyocyte differentiation of human induced pluripotent stem cells // Circulation. 2009. Vol. 120. № 15. P. 1513–23.
  13. Mali P., Yang L., Esvelt K.M., Aach J., Guell M., DiCarlo J.E., Norville J.E., Church G.M. RNA-guided human genome engineering via Cas9 // Science. 2013. Vol. 339. № 6121. P. 823–6.
  14. Cong L., Ran F.A., Cox D., Lin S., Barretto R., Habib N., Hsu P.D., Wu X., Jiang W., Marraffini L.A., Zhang F. Multiplex genome engineering using CRISPR/Cas systems // Science. 2013. Vol. 339. № 6121. P. 819–23.
  15. Ran F.A., Hsu P.D., Wright J., Agarwala V., Scott D.A., Zhang F. Genome engineering using the CRISPR-Cas9 system // Nature Protocols. 2013. Vol. 8. № 11. P. 2281–308.
  16. Soldner F., Laganiere J., Cheng A.W., Hockemeyer D., Gao Q., Alagappan R., Khurana V., Golbe L.I., Myers R.H., Lindquist S., Zhang L., Guschin D., Fong L.K., Vu B.J., Meng X., Urnov F.D., Rebar E.J., Gregory P.D., Zhang H.S., Jaenisch R. Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations // Cell. 2011. Vol. 146. № 2. P. 318–31.
  17. Bellin M., Casini S., Davis R.P., D'Aniello C., Haas J., Ward-van Oostwaard D., Tertoolen L.G., Jung C.B., Elliott D.A., Welling A., Laugwitz K.L., Moretti A., Mummery C.L. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome // EMBO J. 2013. Vol. 32. № 24. P. 3161–75.